Citterio, C.; Biasini, C.; Di Nunzio, C.; Lo Cascio, G.; Cavanna, L.
Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study. Vaccines 2024, 12, 76.
https://doi.org/10.3390/vaccines12010076
AMA Style
Citterio C, Biasini C, Di Nunzio C, Lo Cascio G, Cavanna L.
Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study. Vaccines. 2024; 12(1):76.
https://doi.org/10.3390/vaccines12010076
Chicago/Turabian Style
Citterio, Chiara, Claudia Biasini, Camilla Di Nunzio, Giuliana Lo Cascio, and Luigi Cavanna.
2024. "Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study" Vaccines 12, no. 1: 76.
https://doi.org/10.3390/vaccines12010076
APA Style
Citterio, C., Biasini, C., Di Nunzio, C., Lo Cascio, G., & Cavanna, L.
(2024). Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study. Vaccines, 12(1), 76.
https://doi.org/10.3390/vaccines12010076
